Zuranolone Phase III Clinical Success for Major Depression

news

Sage and Biogen announced today that their GABA receptor modulator Zuranolone achieved primary endpoints in a Phase 3 clinical trial called CORAL

Drug source analysis

Zuranolone is a neurosteroidal GABA-A receptor allosteric modulator that can simultaneously modulate synaptic and outer synaptic GABA receptors by binding to different binding sites of traditional GABA receptor ligands such as BZD and Z-drugs , and therefore may have anticonvulsant, antidepressant, and therapeutic activity in senile degenerative diseases such as AD in addition to hypnosis

Major depression is a serious unmet medical need, and a major advantage of Zuranolone is its rapid onset of action

HAMD-17 consists of 17 indicators, including three categories of insomnia and two categories of anxiety

Consistent with the mechanism of GABA agonists, the main side effects of this product are drowsiness and dizziness, which are said to be nothing compared to the side effects of existing antidepressants